Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969724178> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W1969724178 endingPage "1" @default.
- W1969724178 startingPage "1" @default.
- W1969724178 abstract "Objectives This non-interventional study (RIS-SCH-4023) examined tolerability and effectiveness of risperidone long-acting injectable (RLAI) versus oral second generation antipsychotics (oSGA: amisulpride, aripiprazole, olanzapine, quetiapine, risperidone or ziprasidone) in schizophrenia under daily routine. Methods Outpatients receiving RLAI (n=177) or oSGA (n=257) were followed-up for 2 years (m/f 42%/58%; mean age 34.6 years; duration of disease 2.6 years). Outcome measures included PANSS, CGI, relapse rates, treatment adherence and tolerability. Post-hoc analyses focused on baseline between-group differences. Results Multivariable analysis using recursive partitioning showed that upon study entry RLAI patients were 3.7 times (CI=2.48-5.59) more likely than oSGA patients to have switched to study medication due to non-compliance and/or to be substance abusers (RLAI= 59.9%, n=106/177 vs. oSGA=28.6%, n=73/255). Despite these differences, both groups demonstrated significant improvements in efficacy measures with no between-group differences. There were no significant differences in discontinuation of study medication over the two years (RLAI 41.2% vs. oSGA 36.6%) or in yearly relapse rate before change of the initial therapy (RLAI 0.48±1.48 vs. oSGA 0.71±2.63). In patients with high adherence (≥75%) to previous treatment (physicians’ estimates, 4-point Likert scale) RLAI vs. oSGA patients had significantly better retention rates (RLAI 57.4% vs. oSGA 35.1%) and times (527.0±32.6 vs. 424.1±22.3 days). Most frequently reported treatment-related adverse events were weight increase (13.0% vs. 9.7%), EPS (7.9% vs. 5.5%), hyperkinesia (6.2% vs. 3.5%), fatigue (5.7% vs. 9.7%). Conclusions Results suggest that factors associated with poor outcomes such as poor compliance and substance abuse may be attenuated by treatment with RLAI." @default.
- W1969724178 created "2016-06-24" @default.
- W1969724178 creator A5018798941 @default.
- W1969724178 creator A5067974727 @default.
- W1969724178 creator A5068132580 @default.
- W1969724178 creator A5074778675 @default.
- W1969724178 creator A5085835569 @default.
- W1969724178 date "2010-01-01" @default.
- W1969724178 modified "2023-10-18" @default.
- W1969724178 title "P03-46 - Long-term safety, tolerability and efficacy of risperidone long-acting injectable and oral atypical antipsychotics in schizophrenic patients: two year naturalistic study" @default.
- W1969724178 doi "https://doi.org/10.1016/s0924-9338(10)71156-1" @default.
- W1969724178 hasPublicationYear "2010" @default.
- W1969724178 type Work @default.
- W1969724178 sameAs 1969724178 @default.
- W1969724178 citedByCount "0" @default.
- W1969724178 crossrefType "journal-article" @default.
- W1969724178 hasAuthorship W1969724178A5018798941 @default.
- W1969724178 hasAuthorship W1969724178A5067974727 @default.
- W1969724178 hasAuthorship W1969724178A5068132580 @default.
- W1969724178 hasAuthorship W1969724178A5074778675 @default.
- W1969724178 hasAuthorship W1969724178A5085835569 @default.
- W1969724178 hasConcept C118552586 @default.
- W1969724178 hasConcept C126322002 @default.
- W1969724178 hasConcept C15744967 @default.
- W1969724178 hasConcept C197934379 @default.
- W1969724178 hasConcept C2776412080 @default.
- W1969724178 hasConcept C2776619155 @default.
- W1969724178 hasConcept C2777270317 @default.
- W1969724178 hasConcept C2778375690 @default.
- W1969724178 hasConcept C2778715236 @default.
- W1969724178 hasConcept C2778999636 @default.
- W1969724178 hasConcept C2780057945 @default.
- W1969724178 hasConcept C2780211496 @default.
- W1969724178 hasConcept C2780494398 @default.
- W1969724178 hasConcept C2780634440 @default.
- W1969724178 hasConcept C71924100 @default.
- W1969724178 hasConceptScore W1969724178C118552586 @default.
- W1969724178 hasConceptScore W1969724178C126322002 @default.
- W1969724178 hasConceptScore W1969724178C15744967 @default.
- W1969724178 hasConceptScore W1969724178C197934379 @default.
- W1969724178 hasConceptScore W1969724178C2776412080 @default.
- W1969724178 hasConceptScore W1969724178C2776619155 @default.
- W1969724178 hasConceptScore W1969724178C2777270317 @default.
- W1969724178 hasConceptScore W1969724178C2778375690 @default.
- W1969724178 hasConceptScore W1969724178C2778715236 @default.
- W1969724178 hasConceptScore W1969724178C2778999636 @default.
- W1969724178 hasConceptScore W1969724178C2780057945 @default.
- W1969724178 hasConceptScore W1969724178C2780211496 @default.
- W1969724178 hasConceptScore W1969724178C2780494398 @default.
- W1969724178 hasConceptScore W1969724178C2780634440 @default.
- W1969724178 hasConceptScore W1969724178C71924100 @default.
- W1969724178 hasIssue "S1" @default.
- W1969724178 hasLocation W19697241781 @default.
- W1969724178 hasOpenAccess W1969724178 @default.
- W1969724178 hasPrimaryLocation W19697241781 @default.
- W1969724178 hasRelatedWork W1509131650 @default.
- W1969724178 hasRelatedWork W1985570731 @default.
- W1969724178 hasRelatedWork W1991475958 @default.
- W1969724178 hasRelatedWork W2013970121 @default.
- W1969724178 hasRelatedWork W2044803716 @default.
- W1969724178 hasRelatedWork W2097648013 @default.
- W1969724178 hasRelatedWork W2098103756 @default.
- W1969724178 hasRelatedWork W2159155203 @default.
- W1969724178 hasRelatedWork W2735081669 @default.
- W1969724178 hasRelatedWork W3102273891 @default.
- W1969724178 hasVolume "25" @default.
- W1969724178 isParatext "false" @default.
- W1969724178 isRetracted "false" @default.
- W1969724178 magId "1969724178" @default.
- W1969724178 workType "article" @default.